Purpura: Clinical Trials

69 trials for Purpura, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

24 completed, 20 recruiting, 9 terminated, 7 not yet recruiting. 69 Phase 1, 28 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 169Completed 24, Recruiting 20, Terminated 9, Not yet recruiting 7, Unknown 5, Withdrawn 2, Active not recruiting 1, Enrolling by invitation 1
Phase 228Recruiting 11, Completed 7, Terminated 4, Not yet recruiting 3, Unknown 2, Withdrawn 1

Follow Purpura: new trials by email Literature Review of Purpura trials Research Report on Purpura

Trials (filtered) newest first · largest first

All 69 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias
RXIM002 - Immune Thrombocytopenia (ITP)
Phase 1Not yet recruitingRiboX Therapeutics Ltd.272027-02-012026-10-28
An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1
CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV)
Phase 1 / Phase 2Not yet recruitingUniversity Hospital Tuebingen362027-01-012026-11-12
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA
Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
Phase 1 / Phase 2Not yet recruitingCullinan Therapeutics Inc.722026-12-012026-07-31
TGD001 Treatment in Thrombotic Microangiopathies
TGD001 - Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia
Phase 1 / Phase 2RecruitingTargED Biopharmaceuticals B.V.702026-10-252026-11-12
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
CTX112 - Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia
Phase 1 / Phase 2RecruitingCRISPR Therapeutics AG602026-07-172026-10-20
Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions
SKI-O-703 API in Capsules, SKI-O-703 Formulated Granules in Capsules - Bioequivalence Study in Healthy Subjects, Immune Thrombocytopenia (ITP)
Phase 1Active not recruitingOscotec Inc.482026-07-102026-09-01
A Clinical Study to Evaluate JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia
JCXH-213 - Thrombocytopenic Purpura, Immune
Phase 1Not yet recruitingThe General Hospital of Western Theater Command42026-06-182026-06-03
CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia
Anti-CD20 monoclonal antibody and the BTK inhibitor - Anti-CD20 Monoclonal Antibody, BTK Inhibitors
Phase 1Not yet recruitingQi deng302026-06-012026-05-22
Universal STAR-T Cell Injection in R/R Autoimmune Diseases.
Universal STAR-T Cell - Immune Thrombocytopenia
Phase 1Not yet recruitingJian Zhu62026-05-112026-05-20
Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia
GL-2045 - Immune Thrombocytopenia
Phase 1RecruitingGliknik Inc.422026-04-142026-05-26
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
CM336 Injection - Autoimmune Cytopenia, Immune Thrombocytopenia (ITP)
Phase 1 / Phase 2RecruitingKeymed Biosciences Co.Ltd1582025-11-182025-12-17
Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia
SHR-2173 Injection - Immune Thrombocytopenia
Phase 1RecruitingGuangdong Hengrui Pharmaceutical Co., Ltd102025-11-122026-05-28
An Exploratory Study of Golidocitinib in Adult Patients With ITP
Golidocitinib, Placebo - Immune Thrombocytopenia (ITP)
Phase 1 / Phase 2Not yet recruitingPeking University People's Hospital1382025-10-302025-09-29
OM336 in Autoimmune Cytopenias
OM336 - AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia
Phase 1RecruitingLakefront Biotherapeutics West LLC322025-08-012026-09-03
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Pirtobrutinib, Placebo - Immune Thrombocytopenia (ITP)
Phase 1 / Phase 2RecruitingEli Lilly and Company682025-07-302026-11-04
RN1201 Injection in the Treatment of Antibody-Mediated Diseases
CD19 and BCMA-targeted allogeneic CAR-T cells - Refractory Immune-mediated Platelet Transfusion Refractoriness, Relapsed or Refractory Immune Thrombocytopenia
Phase 1RecruitingThe First Affiliated Hospital of Soochow University92025-07-072026-06-12
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
Budoprutug - Immune Thrombocytopenia (ITP), ITP
Phase 1 / Phase 2RecruitingClimb Bio, Inc.242025-06-302026-03-27
A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
STSA-1301 subcutaneous injection, Placebo - Primary Immune Thrombocytopenia (ITP)
Phase 1 / Phase 2RecruitingJiangsu BioJeTay Biotechnology Co., Ltd.562025-05-122026-08-12
A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia
ESG206 - Immune Thrombocytopenia (ITP)
Phase 1 / Phase 2RecruitingShanghai Escugen Biotechnology Co., Ltd842025-05-082025-05-16
A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
YTS109 cell injection - Lupus Nephritis (LN), Immune Thrombocytopenia (ITP)
Phase 1TerminatedChina Immunotech (Beijing) Biotechnology Co., Ltd.22025-04-162026-10-14

Showing 20 of 69. Sign in to see all of them.

Narrower conditions

Purpura, Thrombocytopenic, Idiopathic (63)  ·  Thrombocytopenia (7)  ·  Anemia, Hemolytic, Autoimmune (5)  ·  Autoimmune Diseases (4)  ·  Anemia, Hemolytic (3)  ·  Arthritis, Rheumatoid (3)  ·  Blood Platelet Disorders (3)  ·  Hematologic Diseases (3)  ·  Purpura, Thrombocytopenic (3)  ·  Antiphospholipid Syndrome (2)  ·  Behcet Syndrome (2)  ·  Dermatomyositis (2)  ·  Evans Syndrome (2)  ·  Immune System Diseases (2)

Broader conditions

Hemic and Lymphatic Diseases (69)  ·  Pathological Conditions, Signs and Symptoms (69)  ·  Signs and Symptoms (69)  ·  Blood Coagulation Disorders (68)  ·  Hemorrhage (68)  ·  Pathologic Processes (68)  ·  Skin Manifestations (68)  ·  Hematologic Diseases (66)  ·  Cytopenia (65)  ·  Blood Platelet Disorders (63)  ·  Hemorrhagic Disorders (62)  ·  Thrombotic Microangiopathies (62)  ·  Immune System Diseases (61)  ·  Purpura, Thrombocytopenic (61)

Interventions

eltrombopag (8)  ·  Rituximab (3)  ·  Staphylococcal Protein A (3)  ·  romiplostim (3)  ·  Tablets (2)  ·  avatrombopag (2)  ·  Acetaminophen (1)  ·  Acetylcysteine (1)  ·  Antigens, CD19 (1)  ·  Atorvastatin (1)  ·  BI 655064 (1)  ·  CD4 Immunoadhesins (1)  ·  Capsules (1)  ·  Ciprofloxacin (1)  ·  Cyclosporine (1)

Sponsors

GlaxoSmithKline (6)  ·  Eisai Inc. (4)  ·  Peking University People's Hospital (4)  ·  Protalex, Inc. (3)  ·  Amgen (2)  ·  Chongqing Peg-Bio Biopharm Co., Ltd. (2)  ·  Chugai Pharmaceutical (2)  ·  Jiangsu HengRui Medicine Co., Ltd. (2)  ·  920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (1)  ·  Alpine Immune Sciences Inc, A Subsidiary of Vertex (1)  ·  Baylor College of Medicine (1)  ·  Bioverativ, a Sanofi company (1)  ·  Boehringer Ingelheim (1)  ·  Bristol-Myers Squibb (1)  ·  CASI pharmaceuticals, Inc. (1)

Countries

United States (28)  ·  China (25)  ·  Spain (10)  ·  United Kingdom (10)  ·  Australia (8)  ·  Germany (7)  ·  Italy (5)  ·  Norway (5)  ·  Poland (5)  ·  Canada (4)  ·  France (4)  ·  Netherlands (4)  ·  Austria (3)  ·  Bulgaria (3)  ·  Hungary (3)

Top investigators

Franklin Johnson (2)  ·  Ann-Christin Pecher (1)  ·  Bhaskar Rege (1)  ·  David T. Teachey, MD (1)  ·  Edo Scahefer, MD (1)  ·  Edward Bernton, MD (1)  ·  Ellis J Neufeld, MD, PhD (1)

Results publications

PMID 19208097, PMID 19846889, PMID 23829485, PMID 24802773, PMID 26504182, PMID 27515248, PMID 29270980, PMID 30171280, PMID 30344993, PMID 32865293, PMID 34452956, PMID 34921514, PMID 35973190, PMID 37028433, PMID 42056497

NIH funding

2014 (2), 2018 (2), 2023 (1), 2025 (1)